<DOC>
	<DOCNO>NCT02484261</DOCNO>
	<brief_summary>This study aim monitor patient relapse leukemia follow allogeneic Hematopoietic Stem Cell Transplantation ( HSCT ) order identify patient early relapse , low burden disease , intervention may successful monitor peripheral blood lineage specific chimerism . Once disease confirm , patient initiate novel combination bortezomib pravastatin .</brief_summary>
	<brief_title>Monitoring Treatment Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation Children</brief_title>
	<detailed_description>Patients enrol study time transplantation . Following HSCT , CD34+ chimerism peripheral blood monitor real time schedule interval . If chimerism CD34+ cell diminish post-HSCT clinical sign symptom relapse leukemia , relapse bone marrow confirm , immunosuppression withdrawn treatment initiate bortezomib pravastatin . Patients monitor disease response 1 year post-HSCT post-study therapy . Patients confirm relapse post-HSCT also eligible enroll receive novel combination .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<criteria>Inclusion Criteria enter study : Voluntary write informed consent patient legal guardian ( appropriate ) performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care Female patient : Are postmenopausal least 1 year Screening visit , OR Are surgically sterile , OR If childbearing potential , agree practice 2 effective method contraception , time , time signing inform consent 30 day last dose study treatment , OR agree completely abstain heterosexual intercourse OR Male patient , even surgically sterilize ( i.e. , status postvasectomy ) , : Agree practice effective barrier contraception entire study treatment period 30 day last dose study treatment , OR Agree completely abstain heterosexual intercourse Lansky ( age &lt; 15 ) /Karnofsky ( age &gt; 16 yr ) performance status &gt; 50 % Hepatic function : total bilirubin ≤ 2.5 mg/dl , ALT/AST &lt; equal 5 x upper limit normal Renal function : Creatinine clearance &gt; 60 ml/min/1.73 m2 ( determined 24 hour collection nuclear ( glomerular filtration rate ) GFR Cystatin C calculation ) Cardiac function : LVEF &gt; 50 % LVSF &gt; 27 % Pulmonary function test : DLCO FEV1 &gt; 50 % ( able perform PFTs , able perform PFTs SAO2 &gt; 94 % room air ) . Acute leukemia Myelodysplastic syndrome ( MDS ) Inclusion Criteria initiate therapy bortezomib pravastatin Lansky performance status ( age &lt; 15 ) /Karnofsky ( age &gt; 16 yr ) performance status &gt; 50 % Hepatic function : total bilirubin ≤ 2.5 mg/dl , ALT/AST &lt; equal 5 x upper limit normal ( ULN ) Renal function : Cr &lt; ULN age Relapse systemic disease document follow : morphology , flow cytometry , cytogenetics and/or FISH . Patient platelet count 20,000/μL within 7 day enrollment . Patients may transfuse prior evaluation may platelet refractory enrollment . Patient absolute neutrophil count great 500 /μL within 7 day enrollment . Patients confirm relapse postHSCT previously enrol monitoring portion protocol , also eligible enroll receive novel combination entry criterion meet time relapse . Patients meet follow exclusion criterion treat study : Patient great equal Grade 2 peripheral neuropathy Patient myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen must document investigator medically relevant . Patient hypersensitivity bortezomib , boron , mannitol . Female patient lactate pregnant . Serious medical psychiatric illness likely interfere participation clinical study . Evidence residual relapse another malignancy ( hematological malignancy indication stem cell transplant ) time transplant preparative regimen initiation Participation clinical trial investigational agent include trial , within 14 day start bortezomib/pravastatin throughout duration therapy . Radiation therapy within 3 week start bortezomib/pravastatin . Enrollment subject require concurrent radiotherapy ( must localize field size ) defer radiotherapy complete 3 week elapse since last date therapy .</criteria>
	<gender>All</gender>
	<minimum_age>22 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>childhood leukemia</keyword>
	<keyword>relapse leukemia</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
</DOC>